NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Parenteral Drugs (India) Limited (NSE: PDPL)

 
PDPL Technical Analysis
1
As on N/A PDPL SHARE Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

PDPLSHARE Price

Open N/A Change Price %
High N/A 1 Day N/A N/A
Low N/A 1 Week N/A N/A
Close N/A 1 Month N/A N/A
Volume N/A 1 Year N/A N/A
52 Week High N/A | 52 Week Low N/A
 
NSE INDIA Most Active Stocks
IDEA 12.90 -2.27%
YESBANK 23.95 0.21%
GTLINFRA 1.75 0.00%
NHPC 87.15 -2.63%
TATASTEEL 162.10 1.28%
SUZLON 39.35 -4.37%
INDUSTOWER 351.40 2.03%
PNB 128.25 -1.00%
SAIL 146.05 0.86%
ZOMATO 189.20 2.16%
 
NSE INDIA Top Gainers Stocks
KMSUGAR 42.45 17.75%
SOLARA 551.75 16.45%
HINDMOTORS 23.70 15.61%
FORCEMOT 9313.85 15.47%
DSSL 1440.95 15.40%
ADFFOODS 215.50 14.29%
CELEBRITY 20.55 11.68%
KSCL 756.80 10.47%
INDOTECH 1732.90 10.00%
HIRECT 737.35 9.99%
 
NSE INDIA Top Losers Stocks
EXCEL 0.50 -9.09%
ANMOL 42.25 -7.85%
SHARDAMOTR 1504.15 -5.41%
TATACOMM 1755.20 -5.33%
JUBLPHARMA 665.00 -5.09%
ARENTERP 52.10 -5.01%
PVP 31.30 -5.01%
PVP 31.30 -5.01%
ARVEE 237.35 -5.00%
GKWLIMITED 2531.05 -5.00%
 
 
PDPL
Daily Charts
PDPL
Intraday Charts
Whats New @
Bazaartrend
PDPL
Free Analysis
 
PDPL Important Levels Intraday
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
RESISTANCE
 
PDPL Target April 2024
4th UP Target
3rd UP Target
2nd UP Target
1st UP Target
1st DOWN Target
2nd DOWN Target
3rd DOWN Target
4th DOWN Target
 
PDPL Weekly Target
4th UP Target
3rd UP Target
2nd UP Target
1st UP Target
1st DOWN Target
2nd DOWN Target
3rd DOWN Target
4th DOWN Target
 
PDPL Target2024
4th UP Target
3rd UP Target
2nd UP Target
1st UP Target
1st DOWN Target
2nd DOWN Target
3rd DOWN Target
4th DOWN Target
 
 
PDPL Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 40.28 Sideways
MFI (14) MFI is Below 20 Over Sold
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is -80.00 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Short Sell 3.12
10 Day Avg Volume Traded 31.81 % More then 10 Day Average Volume
 
PDPL Other Details
Segment BE
Market Capital 131528120.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
PDPL Address
PDPL
 
PDPL Latest News
 
Your Comments and Response on Parenteral Drugs (India) Limited
 
PDPL Business Profile
Parenteral Drugs (India) Limited operates as a healthcare company in India. The company manufactures pharmaceutical products, including intravenous infusion, inhalation, veterinary infusion, etc. It also offers IV fluids, such as carbohydrates and electrolytes, diuretics, dialysis and irrigation solutions, anti-infective and anti-fungal products, and others; and oncology and anaesthesia products. The company also exports its products to Iraq, Yemen, Mozambique, Ghana, Kenya, Kyrgyzstan, Uzbekistan, Sudan, Vietnam, Cambodia, Liberia, Sri Lanka, Nepal, Myanmar, and Cameroon. The company was incorporated in 1983 and is based in Indore, India. Address: Shree Ganesh Chambers, Indore, India, 452001
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service